Skip to main content
Drug bottle and Pill

Compare Skyrizi vs. Humira

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Skyrizi (risankizumab) and Humira (adalimumab) are both injectable medications used to treat inflammatory conditions, but they work differently and have different uses. Skyrizi is an interleukin antagonist that targets IL-23 to reduce inflammation and is used for plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. Humira, on the other hand, is a biologic DMARD that blocks TNF, another protein involved in inflammation, and is used for a wider range of conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, and more. Skyrizi is typically administered every 2 to 3 months after initial doses, while Humira is usually given every other week. Skyrizi is only available as a brand-name medication, whereas Humira has several biosimilars. Both medications can increase the risk of infections, but Humira also has warnings for potential cancer risks and nervous system effects. Skyrizi is not approved for use in children, while Humira can be used in young children for certain conditions.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.